Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Talking about Morgan ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (NYSE:LLY) is scheduled to release its earnings report on Thursday, May 1, 2025. For event-driven traders, historical stock performance following earnings announcements may offer ...

Shares of Eli Lilly and Company (NYSE: LLY) skyrocketed 59% in 2023. The big drugmaker delivered its second-best stock performance in the last 25 years, eclipsed only by a gain of nearly 64% in 2021.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Mega-Cap Movers (Market Cap $200B+): Large-Cap Stock Movers (Market Cap $10B-$200B): New Providence Acquisition Corp N (ASTS): +8.77% CoreWeave (CRWV): CoreWeave stock initiated with Reduce rating by ...

Lilly's forward price-to-earnings (P/E) ratio currently tops 35, which is more than twice the average of 15.8 for the healthcare industry. 3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating today. Geoff Meacham has given his Buy rating due to a combination of factors ...